Dynavax Technologies (DVAX) Scheduled to Post Earnings on Wednesday

Dynavax Technologies (NASDAQ:DVAX) is scheduled to be releasing its earnings data after the market closes on Wednesday, May 8th. Analysts expect Dynavax Technologies to post earnings of ($0.04) per share for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Dynavax Technologies Stock Up 0.2 %

Shares of Dynavax Technologies stock opened at $11.74 on Monday. The firm’s 50-day moving average price is $12.14 and its two-hundred day moving average price is $13.07. The company has a current ratio of 13.81, a quick ratio of 12.96 and a debt-to-equity ratio of 0.41. Dynavax Technologies has a 12-month low of $10.57 and a 12-month high of $15.15.

Insider Activity

In related news, CAO Justin Burgess sold 20,526 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $12.78, for a total transaction of $262,322.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 2.98% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently commented on DVAX. StockNews.com cut shares of Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Friday, April 26th. The Goldman Sachs Group initiated coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 target price for the company. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $25.00.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.